Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Undergraduate Student Perspectives on Medicinal Chemistry and Drug Discovery Research.

Journal of medicinal chemistry·2026
Same author

From Serendipity to Rationality: Expanding Druggability by Molecular Glue Discovery.

Journal of medicinal chemistry·2026
Same author

Chronic Co-administration of Methylphenidate and Fluoxetine Reduces Striatal NMDA Receptor Binding in Adolescent Rats.

Neurochemical research·2026
Same author

Small-Molecule Drug Discovery Targeting RNAs: Hope or Hype?

Journal of medicinal chemistry·2026
Same author

Structural Studies of Fourth-Generation EGFR Inhibitors Reveal Insights into Selective T790M and C797S Targeting.

ACS medicinal chemistry letters·2026
Same author

Structural Biology Enabling Drug Discovery.

Journal of medicinal chemistry·2025

Related Experiment Video

Updated: Sep 11, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Profiling and Optimizing Targeted Covalent Inhibitors through EGFR-Guided Studies.

Tahereh Damghani1, Surbhi P Chitnis1, Omobolanle A Abidakun1

  • 1Department of Chemistry, The State University of New York at Buffalo, Buffalo, New York 14260, United States.

Journal of Medicinal Chemistry
|August 13, 2025
PubMed
Summary

Targeted covalent inhibitors (TCIs) show promise in drug discovery. Optimizing TCIs involves balancing inactivation efficiency and selectivity, not just maximizing speed, for better clinical outcomes.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay
06:17

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Published on: February 28, 2025

674

Related Experiment Videos

Last Updated: Sep 11, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay
06:17

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Published on: February 28, 2025

674

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Drug Discovery

Background:

  • Targeted covalent inhibitors (TCIs) are crucial in drug discovery for sustained target engagement and clinical effectiveness.
  • Systematic design strategies and practical optimization guidance for TCIs are underdeveloped.
  • Kinetic parameters are key for TCI optimization but require deeper understanding.

Purpose of the Study:

  • To elucidate structural and functional factors for optimizing irreversible TCIs using EGFR kinase as a model.
  • To provide practical guidance for TCI design and compound prioritization.
  • To explore the balance between inactivation efficiency and selectivity in TCI optimization.

Main Methods:

  • Utilized EGFR kinase as a model system for studying TCIs.
  • Performed functional analyses to understand TCI optimization phases.
  • Conducted structural studies to identify selectivity determinants.
  • Analyzed kinetic parameters including inactivation efficiency rate (k_inact/K_I).

Main Results:

  • Identified a two-phase optimization process for TCIs.
  • Demonstrated that balancing inactivation efficiency (k_inact/K_I) is more effective than maximizing it.
  • Achieved selective inhibition of EGFR L858R/T790M mutants over wild-type by tuning kinetic parameters.
  • Discovered hydrophobic and hydrophilic interactions critical for L858R/T790M selectivity.

Conclusions:

  • A balanced approach to TCI optimization, considering both kinetics and selectivity, is crucial.
  • Structure-guided design principles can be applied to enhance TCI selectivity.
  • Integrating kinetic and selectivity data is vital for successful TCI discovery campaigns.